MedPath

IAGARU ANDREI

🇮🇹Italy
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:0
Completed:11

Trial Phases

2 Phases

Phase 1:4
Phase 2:10

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 2
10 (71.4%)
Phase 1
4 (28.6%)

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Phase 2
Recruiting
Conditions
Parathyroid Adenoma
Interventions
Drug: 18Fluorocholine
First Posted Date
2023-06-07
Last Posted Date
2024-04-17
Lead Sponsor
Andrei Iagaru
Target Recruit Count
100
Registration Number
NCT05891769
Locations
🇺🇸

Stanford Hospital and Clinics, Stanford, California, United States

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

Phase 1
Recruiting
Conditions
Head and Neck Cancer
Interventions
Procedure: Single photon emission computed tomography/computed tomography (SPECT/CT) scans
First Posted Date
2021-04-12
Last Posted Date
2025-05-06
Lead Sponsor
Andrei Iagaru
Target Recruit Count
28
Registration Number
NCT04840472
Locations
🇺🇸

Stanford University, Stanford, California, United States

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
Drug: 68-Ga RM2.
Drug: 68-Ga PSMA11
Device: PET/MRI
First Posted Date
2020-02-11
Last Posted Date
2024-02-01
Lead Sponsor
Andrei Iagaru
Target Recruit Count
4
Registration Number
NCT04264208
Locations
🇺🇸

Stanford Cancer Center, Stanford, California, United States

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: 68-Ga RM2
Drug: 68-Ga PSMA11
Device: Investigational software and coils in PET/MR Scan
Procedure: PET/MRI
First Posted Date
2019-05-14
Last Posted Date
2024-01-30
Lead Sponsor
Andrei Iagaru
Target Recruit Count
14
Registration Number
NCT03949517
Locations
🇺🇸

Stanford University, Stanford, California, United States

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Phase 1
Completed
Conditions
Estrogen Receptor Positive
Breast Carcinoma
Interventions
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Device: Investigational software and coils in PET/MR scan
First Posted Date
2019-02-06
Last Posted Date
2023-12-13
Lead Sponsor
Andrei Iagaru
Target Recruit Count
5
Registration Number
NCT03831711
Locations
🇺🇸

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.